EyePoint Inc

Financials

Flujo de caja de las actividades operativas -35.85 M-53.12 M-62.59 M-59.35 M-65.05 M -240.11 M Flujo de caja de las actividades de inversión -95.96 M39.52 M48.34 M55.38 M-74.67 M 68.58 M Flujo de caja de las actividades financieras 151.69 M-951 K238 K7.4 M166.96 M 173.65 M Flujo de caja libre -36.23 M-53.4 M-63.81 M-60.15 M-66.03 M -243.39 M

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

EYPT

Financials

EyePoint Inc

Noticias

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

EyePoint Pharmaceuticals en conferencia RBC: avances estratégicos en oftalmología

Guggenheim reitera calificación de acciones de EyePoint por datos de seguridad de Duravyu

Guggenheim reitera calificación de acciones EyePoint por datos de seguridad

Guggenheim reiterates EyePoint stock rating on Duravyu safety data

Mizuho mantiene calificación de Mejor Rendimiento para EyePoint

EyePoint stock rating maintained at Outperform by Mizuho

H.C. Wainwright eleva el precio objetivo de EyePoint a 30 dólares

H.C. Wainwright eleva precio objetivo de EyePoint a $30 por avance en DME

H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress

EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT)

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript